Work Experience

  • Todate 2011

    Doçent

    Marmara Üniversitesi Eczacılık Fakültesi, Klinik Eczacılık AD

  • 2011 2003

    Yardımcı Doçent

    Marmara Univ. Eczacılık Fakültesi, Farmakoloji AD - Klinik Eczacılık BD

  • 2003 1994

    Araştırma Görevlisi

    Marmara Üniversitesi Eczacılık Fakültesi, Farmakoloji AD - Klinik Eczacılık BD

Education & Training

  • Ph.D. 2001

    Klinik Eczacılık / Clinical Pharmacy

    Marmara Univ

  • Master1995

    Klinik Eczacılık / Clinical Pharmacy

    Marmara Univ

  • Bachelor1992

    Eczacılık / Pharmacy

    İstanbul Univ

Honors, Awards and Grants

  • 2012
    Marmara Üniversitesi Eczacılık Fakültesi Üstün Başarı Ödülü
    image
  • 2011
    Marmara Üniversitesi Sağlık Bilimleri Enstitüsü Yayın Teşvik Ödülü:
    image
  • 2016
    M.Ü. Sağlık Bilimleri Enstitüsü Tez Kaynaklı Uluslararası Yayın Ödülü
    image
  • 2013
    Marmara Üniversitesi Rektörlüğü 130. Kuruluş Yıldönümü Akademik Başarı Ödülü
    image
  • 2006
    Genç Akademisyen Ödülü: Tüm Eczacı Kooperatifleri Birliği, Güncel Eczacılık, M.Ü. Eczacılık Mezunları Derneği ve SO Ofis tarafından verilen 3. Eczacılık Ödülleri
    image
  • 2012
    Poster Ödülü: Serbest Eczanede Varfarin Kullanan Hastaların Bilgi Düzeyinin Değerlendirilmesi ve Eczacının Rolü". 11. Türkiye Eczacılık Kongresi,
    image

Research Projects

  • image

    İzoniazid, Pirazinamid ve Rifampisinin kanda tayini ve tüberküloz hastalarında izlenmesi. Marmara.Üniversitesi Bilimsel Araştırma Projesi, 2005. (Katılımcı)

  • image

    Subakut Sklerozan Panensefalit (SSPE) Hastalarında Aprepitantın Güvenlilik ve Etkililiğini İnceleyen Faz II Randomize, Plasebo-Kontrollü, Klinik Çalışma, TÜBİTAK PROJESİ, Araştırmacı, 2014 (Devam ediyor)

  • image

    Eskişehir Seyitgazi Bardakçı Köyü’nün İçinden Canlandırma Projesi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu, Eğitim Bilimleri (BAPKO), 2013 (Katılımcı)

  • image

    Sıçanlarda Bazı Nonsteroidal Antiinflamatuar İlaçların Nefrotoksisitesi, Marmara Üniversitesi Araştırma Fonu, 1998.

  • image

    Curcumin ve Melatoninin Dosetaksel-Dirençli Antiandrojen Bağımsız Prostat Kanser Hücrelerindeki Çeşitli Mikro-RNA Düzeyleri Üzerine Etkilerinin İncelenmesi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu (BAPKO), 2012 (Devam ediyor)

  • image

    Seçici Serotonin Gerialım İnhibitörü Kullanan Hastalarda Cyp2c19 Polimorfizmleri İle Advers İlaç Reaksiyonu Ve Hasta Uyuncu İlişkisi, BAPKO, Sağlık Bilimleri C tipi (Yüksek Lisans) Projesi, 2013

  • image

    Diyabetli Hayvanlarda Cotinus coggygria’lı Merhemin Yara İyileştirici Etkisi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu, Sağlık Bilimleri (BAPKO), 2012 (Katılımcı)

  • image

    International Drug Utilization Survey on Acute Myocardial Infarction Management - Collaborative Project, 1998 (Avrupa Klinik Eczacılık Derneği (ESCP) projesi (Katılımcı)

  • image

    Cotinus coggygria scop etanol ekstresinden hazırlanan merhemin deney hayvanlarında yara iyileştirici etkisinin incelenmesi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu, Sağlık Bilimleri, BAPKO 2012 (Katılımcı)

  • image

    Tüberküloz Tedavisi Alan Çocuk Hastalarda Terapötik İlaç İzlemi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu (BAPKO), Sağlık Bilimleri A tipi proje, 2011 (Devam ediyor)

  • image

    Nigella sativa yağının deney hayvanlarında yara iyileşmesine etkisinin biyokimyasal yönden incelenmesi, Marmara Üniversitesi Bilimsel Araştırma Projeleri Komisyonu (BAPKO), 2009 (Katılımcı)

Filter by type:

Sort by year:

Ethanol extract of Cotinus coggygria leaves accelerates wound healing process in diabetic rats.

Original Article Pharm Biol. , Volume 54, Issue 11, 2016, Pages 2732-2736.

Abstract

CONTEXT: Cotinus coggygria Scop. (Anacardiaceae) leaves that were used as wound healing in traditional Balkan and Anatolian folk medicine, could be potentially effective in treating diabetic wounds. OBJECTIVE: This study investigates biochemical and histological effects of ethanol extract of C. coggygria (CCE) on excision wound model in diabetic rats. MATERIALS AND METHODS: This study was conducted on diabetic Wistar albino rats, which were injected by a single dose (50?mg/kg i.p.) streptozotocin. Afterward an excision wound model was created in all animals; diabetic control rats were applied topically simple ointment and diabetic treatment rats were applied topically 5% (w/w) ointment with CC, once a day during the experimental period. Malondialdehyde, glutathione and hydroxyproline levels in wound tissues were investigated at the end of 3rd, 7th, and 14th days. Histopathological examination was also performed. RESULTS: Hydroxyproline content was significantly increased in the CCE treated group versus control after the 3rd and 7th days (15.33 versus 11.83; 19.67 versus 15.67?mg/g, p?<?0.05; respectively). A statistically significant elevation in glutathione at the end of 3rd, 7th, and 14th days (5.13 versus 1.58, p?<?0.05; 4.72 versus 1.88, p?<?0.05; 3.83 versus 1.88?µmol/g, p?<?0.05, respectively) and a statistically significant decrease in malondialdehyde level at the end of 7th day (4.49 versus 1.48?nmol/g, p?<?0.05) were determined in the treated group versus control group. These results were also supported by histological analyses. DISCUSSION AND CONCLUSION: These findings indicate that CCE accelerated the cutaneous wound healing process in diabetic wounds, in confirmation of its traditional use.


Özet

Validation of the Turkish version of medication regimen complexity index among elderly patients.

Original Article J Eval Clin Pract., Volume 22, Issue 5, 2016, Pages 732-6.

Abstract

OBJECTIVE: The aim of this study was to validate the Turkish version of the 'Medication Regimen Complexity Index' (MRCI). METHODS: This validation study has been conducted in prescriptions of the first 100 elderly patients who had visited the pharmacy for their prescription refill to evaluate convergent and divergent validity of the Turkish version. The reliability of the Turkish version was assessed with inter-rater and test-retest analysis after its translation and cultural adaptation. RESULTS: The mean age of the 100 patients (53 women) was 74.9?years (SD?=?7.58, 65-95). The scale showed high inter-rater reliability and test-retest reliability for the total and subscale scores (p?<?0.05). A strong and positive correlation between the number of medications in a prescription and the total Medication Regimen Complexity Index scores (r?=?0.930, p?<?0.001) was determined. There were no statistically significant differences between age, gender and MRCI scores (p?>?0.05). CONCLUSION: These results show that the Turkish version of MRCI is a reliable and valid tool in elderly patients.


Özet

Determination of CYP2C19 Polymorphism, Side Effects, and Medication Adherence in Patients Who have Utilized Selective Serotonin Reuptake Inhibitors

Original Article Bulletin of Clinical Psychopharmacology , Volume 26, Issue 2, 2016, Pages 93-214

Abstract

Objective: The aim of this study is to determine relationship of cytochrome P-450 2C19 (CYP2C19) enzymes polymorphism, side effects, and medication adherence in patients who have been diagnosed with major depression and have utilized selective serotonin reuptake inhibitors. Methods: Fifty-three major depression patients (mean of age: 33.25±11.29 years old; male/female: 7/46) were included in this study. Polymorphisms were determined from genomic DNA by using the ‘Real-Time Polymerase Chain Reaction’ method. Side effects and medication adherence levels were assessed by using the ‘Toronto Side Effects Scale’ and the four items medication adherence scale (Morisky, Green and Levine), respectively. Results: The most common side effects that patients reported were drowsiness/daytime somnolence (54.7%), malaise or fatigue (43.4%), sweating (43.4%), nausea (41.5%) and dry mouth (41.5%). Only nine (17%) patients were found to be highly adherent to their medication. When evaluating the CYP2C19 polymorphisms of patients, 37.7%, 24.5% and 20.8% of the patients were classified as intermediate, extensive and ultra-rapid metabolizers, respectively. Allele frequencies of CYP2C19*17 and CYP2C19*2 was calculated as 24.5% and 27.4%, respectively. Although there were some differences in side effect scores and medication adherences among the polymorphism groups, these relationships were not found to be statistically significant. Conclusion: This study shows that patients who utilized antidepressants frequently experienced side effects and had low medication adherence. Another interesting finding is the high rate of ultrarapid metabolizers of CYP2C19.


Özet

Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.

Original Article Int J Clin Pharm. , Volume 38, Issue 6, 2016, Pages 1464-1476.

Abstract

Background International guidelines are tools enabling physicians to incorporate the latest evidence based clinical information into practice. Objective This study aimed to evaluate the impact of antiemetic guidelines adherence on the incidence of chemotherapy-induced nausea and vomiting (CINV) and patient quality of life. Setting Marmara University Pendik Training and Research Hospital chemotherapy unit, Istanbul, Turkey. Method The study included 100 chemotherapy naive patients. Antiemetic prescribing patterns and their consistency with MASCC/ESMO 2014 guidelines were assessed. Patients recorded incidences of vomiting in a daily dairy and described their nausea using a 7-item Likert Scale. The incidence of CINV was recorded over five days. To assess the patient's quality of life, a modified Turkish version of the Functional Living Index-Emesis (FLIE) questionnaire was administered before and after receiving chemotherapy. A questionnaire on the existence and severity of side effects was developed and administered. Main outcome measures Incidence of side effects on CINV and quality of life according to the FLIE. Results The primary outcome revealed differences in complete control (no emetic episodes, rescue therapy or nausea), FLIE scores and side effects. Guidelines consistency was observed more with acute (A) than with delayed (D) prevention of CINV, with significant differences in complete control between the guideline adherent group (GAG) and the guideline nonadherent group (GNG). Significant differences in the FLIE score were noticed between GAG(D) and GNG(D), and GNG(D) had a higher incidence of diarrhoea, headache, swallowing difficulties and dark-coloured stool. Conclusion Consistency with guidelines resulted in significant reduction in the incidence of both cute and delayed CINV and other side effects, and with improvement of the patient quality of life.


Özet

Translation and psychometric evaluation of the Turkish version of the pharmacy students’ perceptions of preparedness to provide pharmaceutical care scale.

Original Article Pharmazie, Volume 71 (, Issue 10, 2016, Pages 613-616.

Abstract

The aim of the study is to conduct the psychometric evaluation of the Turkish version of the Pharmacy Students’ Perceptions of Preparedness to Provide Pharmaceutical Care (PREP) scale. The present study was conducted at three faculties of pharmacy among fifth-year students during a three-month period in 2015. After the translation process, the Turkish version was developed. Psychometric evaluation consisted of the calculation of inter-rater and test-retest reliability and factor analysis. The mean age of 184 students (71.2% of female) was 23.74±1.07. The mean score of the Pharmacy Students’ PREP scale was 4.54±1.00 and the Cronbach’s alpha was 0.971. Inter-rater and test-retest reliability and factor analysis were also in concordance with the literature. In the present study, the Turkish version of Pharmacy Students’ Perceptions of Preparedness to Provide Pharmaceutical Care Scale has been determined to be a reliable and validated tool to assess students’ perceptions of preparedness to provide pharmaceutical care.


Özet

Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.

Review Expert Opin Drug Saf., Volume 15, Issue 2, 2016, Pages 223-36.

Abstract

INTRODUCTION: Many systematic reviews resulted in claims on drug-drug interactions (DDIs) with proton pump inhibitors (PPIs). Such a large number begs for consensus on the clinical significance of findings. AREAS COVERED: We critically evaluated the safety of PPI use with respect to DDIs with a meta-review of systematic reviews published between 1978 and 2015. We assessed the evidence by their reliability, repeatability, transparency, and objectivity according to the Assessment of Multiple Systematic Reviews (AMSTAR) criteria. EXPERT OPINION: Clinicians must assess risks for each PPI for certain comorbid conditions. DDIs don't substantiate class effect for PPIs; each PPI could induce unique DDIs. Concomitant use of PPIs with thienopyridines (e.g. clopidogrel) could be justified in patients without strong affinity to cytochrome CYP2C19 and with high risk of bleeding (e.g. patients with prior upper gastrointestinal bleeding, Helicobacter pylori infection, advanced age, steroid treatment, and nonsteroidal anti-inflammatory drug use). DDIs could occur in an AIDS subpopulation treated with highly active antiretroviral therapy (HAART). DDIs exist for cancer patients undergoing targeted therapy. Hypomagnesemia could increase in the setting of advanced age and polypharmacy. Omeprazole poses high risks owing to its pharmacokinetic DDI profile. Future systematic reviews should incorporate these additional risks for better clinical guidance.


Özet

Currrent Teaching

  • 2018 GÜZ

    CLINICAL PHARMACY-I

    -

Teaching History

  • 2016 GÜZ

    CASE ANALYSIS - I

    ---

  • 2015 GÜZ

    CLINICAL PHARMACY APPLICATION - II

    -

  • 2015 GÜZ

    CLINICAL PHARMACY-II

    Yok

  • 2017 BAHAR

    MASTER THESIS

    -

  • 2017 GÜZ

    GRADUATION PROJECT

    --

  • 2016 GÜZ

    GRADUATION PROJECT

    --

  • 2015 GÜZ

    CASE ANALYSIS - II

    -

  • 2015 GÜZ

    RATIONAL DRUG USE IN HOSPITALS-II

    -

  • 2016 BAHAR

    CLINICAL PHARMACY II

    Yok

  • 2016 GÜZ

    CLINICAL PHARMACY-I

    -

  • 2014 BAHAR

    CLINICAL PHARMACY II

    Yok

  • 2015 BAHAR

    CLINICAL PHARMACY II

    Yok

  • 2016 BAHAR

    CLINICAL PHARMACY-II

    Yok

  • 2016 GÜZ

    CLINICAL PHARMACY I

    -

  • 2015 BAHAR

    CLINICAL PHARMACY II*

    -

  • 2015 GÜZ

    CLINICAL PHARMACY I

    -

  • 2016 BAHAR

    CLINICAL PHARMACY II*

    -

  • 2017 BAHAR

    CLINICAL PHARMACY-II

    Yok

  • 2017 GÜZ

    CLINICAL PHARMACY-II

    Yok

  • 2017 GÜZ

    CASE ANALYSIS - II

    -

At My Office

Ders zamanları dışında Eczacılık Fakültesi 1. katında bulunan toplantı odasında bulunmaktadır.